文献速递心力衰竭与心肌病

非奈利酮在射血分数轻度降低或保留心衰中跨射血分数谱的疗效与安全性:FINEARTS-HF预设分析

Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial.
PubMed 文献 · Circulation · 2024-09-29

FINEARTS-HF预设分析纳入5993例LVEF≥40%的心衰患者,按LVEF<50%、50%至<60%、≥60%分层评估非奈利酮疗效。非奈利酮降低心血管死亡与总心衰事件风险在各LVEF类别中一致,交互P=0.70,连续变量分析交互P=0.28,获益不随LVEF改变。

要点

  • 非奈利酮在LVEF≥40%心衰中降低心血管死亡与总心衰事件,获益不随LVEF分层改变。
  • 各LVEF类别风险比分别为0.84、0.80、0.94,交互P=0.70。
  • LVEF作为连续变量分析亦未见疗效修饰,交互P=0.28。

核心结论

  • 在射血分数轻度降低或保留的心衰患者中,非奈利酮降低心血管死亡与心衰恶化事件风险,且不随LVEF改变。

研究设计与样本

  • FINEARTS-HF为随机、安慰剂对照试验,评估非奈利酮在LVEF≥40%心衰患者中的疗效与安全性。
  • 本分析为预设分析,按LVEF<50%、≥50%至<60%、≥60%分层并以LVEF连续变量评估疗效。
  • 6001例参与者中5993例有基线LVEF数据,平均LVEF 53±8%,中位53%(四分位距46%-58%)。

主要发现

  • LVEF<50%者2172例(36%),50%至<60%者2674例(45%),≥60%者1147例(19%)。
  • 非奈利酮降低心血管死亡与总心衰事件风险在各LVEF类别一致:<50%率比0.84(95%CI 0.68-1.03),≥50%至<60%率比0.80(0.66-0.97),≥60%率比0.94(0.70-1.25),交互P=0.70。
  • LVEF作为连续变量未见疗效修饰(交互P=0.28);对心衰恶化事件总数的影响亦一致(连续交互P=0.26)。
  • 较高LVEF患者更年长、女性更多、冠心病史较少,高血压与慢性肾脏病史更常见。

临床怎么用

  • 对LVEF≥40%的心衰患者,非奈利酮的获益不因LVEF分层而异,可按整体试验人群结论应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effects of treatments for heart failure (HF) may vary among patients according to left ventricular ejection fraction (LVEF). In FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure), the nonsteroidal mineralocorticoid receptor antagonist finerenone reduced the risk of cardiovascular death and total worsening HF events in patients with HF with mildly reduced or preserved ejection fraction. We examined the effect of finerenone according to LVEF in FINEARTS-HF. METHODS: FINEARTS-HF was a randomized, placebo-controlled trial examining the efficacy and safety of finerenone in patients with HF and LVEF ≥40%. The treatment effect of finerenone was examined in prespecified analyses according to LVEF categories (<50%, ≥50% to <60%, and ≥60%) and with LVEF as a continuous variable. The primary outcome was a composite of total (first and recurrent) worsening HF events and cardiovascular death. RESULTS: Baseline LVEF data were available for 5993 of the 6001 participants in FINEARTS-HF. Mean and median LVEF were 53±8% and 53% (interquartile range, 46%-58%), respectively. LVEF was <50% in 2172 (36%), between 50% and <60% in 2674 (45%), and ≥60% in 1147 (19%). Patients with higher LVEF were older, were more commonly female, were less likely to have a history of coronary artery disease, and more frequently had a history of hypertension and chronic kidney disease compared with those with a lower LVEF. Finerenone reduced the risk of cardiovascular death and total HF events consistently across LVEF categories (LVEF <50% rate ratio, 0.84 [95% CI, 0.68-1.03]; LVEF ≥50% to <60% rate ratio, 0.80 [0.66-0.97]; and LVEF ≥60% rate ratio, 0.94 [0.70-1.25]; Pinteraction=0.70). There was no modification of the benefit of finerenone across the range of LVEF when analyzed as a continuous variable (Pinteraction=0.28). There was a similar consistent effect of finerenone on reducing the total number of worsening HF events (continuous Pinteraction=0.26). CONCLUSIONS: In patients with HF with mildly reduced or preserved ejection fraction, finerenone reduced the risk of cardiovascular death and worsening HF events, irrespective of LVEF. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04435626. URL: https://eudract.ema.europa.eu; Unique identifier: 2020-000306-29.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Docherty, Henderson, Jhund, et al. Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. Circulation. 2024. PMID: 39342512. doi:10.1161/CIRCULATIONAHA.124.072011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。